Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 in IDH-mutated hematological malignancies
NCT04764474Phase 1Terminated
- Sponsor
- HUTCHMED
- Start
- Apr 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ranosidenib in acute myeloid leukemia (AML) and hematological malignancies, sponsored by HUTCHMED. Primary endpoints: Recommended Phase 2 Dose at 28 days, Dose-Limiting Toxicities at 28 days and 1 more. Started Apr 2021; status: terminated.
02
Drugs
ranosidenib
03
Conditions
acute myeloid leukemia (AML)hematological malignancies
Beyond the preview
Go deeper on NCT04764474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764474.